Andrew Huberman Peptides: What He Takes & Why

Key Takeaways

Huberman personally uses sermorelin (3–5 nights per week before bed) for deeper sleep and recovery
He used BPC-157 to treat a herniated disc — reported pain relief within two injections
He categorizes peptides into tissue repair (BPC-157, TB-500), growth hormone secretagogues (sermorelin, tesamorelin, ipamorelin), and others
He consistently warns about the tumor growth risk with peptides that promote angiogenesis

Why Huberman’s Take Matters
Peptides Huberman Personally Uses
Peptides He Discusses But Doesn’t Take
Huberman’s Peptide Categories
Specific Podcast Episodes and Timestamps
Huberman on GH Secretagogues vs. Direct HGH
Deeper Look at His Sermorelin Protocol
Peptides He’s Been Asked About But Doesn’t Recommend
His Warnings and Caveats
The FDA Reclassification Factor
How to Get Peptides Prescribed
FAQ
Sources

Andrew Huberman is a neuroscientist and professor of neurobiology at Stanford University. He runs the Huberman Lab podcast, one of the most popular science podcasts in the world. When he dedicated a full episode to peptides in April 2024 — “Benefits & Risks of Peptide Therapeutics for Physical & Mental Health” — it became one of his most-listened episodes.

What makes Huberman different from most peptide influencers: he reads the actual studies, distinguishes between animal and human data, and is blunt about what we don’t know. He’s also openly used peptides himself, giving him both the scientific lens and personal experience.

If you’re new to peptide therapy in general, start there for the fundamentals before diving into Huberman’s specific protocol.

Peptides Huberman Personally Uses

Sermorelin: His Sleep and Recovery Protocol

Sermorelin is the peptide Huberman has discussed most openly as part of his own routine. It’s an FDA-approved growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce more human growth hormone naturally [1].

In a 2023 podcast appearance, Huberman shared that he takes sermorelin 3 to 5 nights per week, injected subcutaneously before bed.

His reported effects:

Deeper sleep. He describes falling into more restorative sleep, though notes it’s often more “truncated and intense” with vivid dreams.
Better recovery from exercise. He felt his body bounced back faster from training sessions.
No noticeable body composition changes. Despite what some marketing claims suggest, Huberman says he didn’t see significant fat loss or muscle gain from sermorelin alone.

That last point is worth highlighting. A lot of peptide marketing promises dramatic body recomposition from GH secretagogues. Huberman’s honest assessment — “improved sleep and recovery, but no dramatic physical changes” — matches what the clinical literature actually supports [2].

For more on what to expect, our sermorelin benefits guide covers the research in detail.

BPC-157: Fixing a Herniated Disc

Huberman’s BPC-157 story is one of the more compelling personal testimonials from a credible source. He had a herniated disc causing persistent lower back pain. Massage, heat therapy, and electrical stimulation all failed to resolve it.

He started injecting BPC-157 and reported that within two injections, his back pain was completely resolved — to a degree that months of other therapies couldn’t achieve.

That’s a dramatic claim, and Huberman is careful to frame it properly. He emphasizes that BPC-157 research is almost entirely in animal models [3]. “There isn’t any clinical data for BPC-157. It’s all animals,” he stated on his podcast. His personal experience was positive, but he doesn’t position it as proof.

BPC-157 works through multiple mechanisms: promoting angiogenesis (new blood vessel formation), modulating inflammation, and influencing growth factors like VEGF and EGF that drive tissue regeneration [4]. These mechanisms explain why it shows broad healing effects across tendons, ligaments, muscles, and gut tissue in rodent studies.

For dosing specifics, see our BPC-157 dosing guide.

Peptides He Discusses But Doesn’t Take

TB-500 (Thymosin Beta-4)

Huberman covers TB-500 extensively in his peptide episode. He explains it as a tissue repair peptide that works through different mechanisms than BPC-157 — primarily by upregulating actin (a structural protein that helps cells migrate to wound sites) and promoting systemic healing rather than localized repair [5].

He discusses the BPC-157 and TB-500 stack that many practitioners use, noting their complementary mechanisms. BPC-157 tends to work more locally; TB-500 spreads systemically due to its smaller molecular weight.

Ipamorelin

Huberman classifies ipamorelin as a growth hormone releasing peptide (GHRP) that stimulates GH release from the pituitary. He discusses it alongside sermorelin as a secretagogue option, noting that ipamorelin’s benefits include a cleaner GH release profile with less impact on cortisol and prolactin than older GHRPs [6].

CJC-1295 and Tesamorelin

In his episode with Dr. Craig Koniver (October 2024), Huberman explored the CJC-1295 + ipamorelin combination and tesamorelin as GH secretagogue options. Tesamorelin is FDA-approved for reducing visceral fat in HIV patients, which gives it stronger clinical data than most peptides in this space [7].

Pentadeca Arginate (PDA)

In the Koniver episode, Huberman discussed Pentadeca Arginate as a potential alternative to BPC-157 following the FDA’s compounding restrictions. Since BPC-157 became harder to obtain through compounding pharmacies, some practitioners have turned to PDA as a related compound. Huberman asked Koniver directly about combining tesamorelin or sermorelin with ipamorelin and “not BPC anymore, but Pentadeca Arginate instead, because you can’t get BPC-157 compounded.”

This highlights the shifting regulatory picture — for current legal status, see our guide on whether peptides are legal.

Huberman’s Peptide Categories

In his April 2024 episode, Huberman organized the confusing peptide space into clear categories:

Category 1: Tissue Repair and Regeneration

BPC-157 — promotes angiogenesis, fibroblast migration, and cell turnover
TB-500 (Thymosin Beta-4) — systemic healing, actin upregulation

These work by accelerating the body’s natural repair processes. They don’t build muscle or burn fat directly — they help injured tissue heal faster.

Category 2: Growth Hormone Secretagogues

Sermorelin (FDA-approved) — stimulates pituitary GH release
Tesamorelin (FDA-approved) — similar mechanism, stronger visceral fat data
CJC-1295 — longer-acting GHRH analog
Ipamorelin — GHRP with clean side effect profile
MK-677 (Ibutamoren) — oral GH secretagogue (technically not a peptide)

These stimulate your body’s own growth hormone production rather than replacing it with exogenous GH. The distinction matters — natural pulsatile GH release is safer than flat-line exogenous dosing [8].

Category 3: Other Peptides Discussed

Huberman has mentioned various other peptides in guest conversations, including those for cognitive function, immune support (Thymosin Alpha-1), and sexual health (PT-141).

Specific Podcast Episodes and Timestamps

Huberman has discussed peptides across multiple episodes. Here’s where to find his key statements:

Episode 1: “Benefits & Risks of Peptide Therapeutics for Physical & Mental Health” (April 1, 2024) — This is the definitive episode. Over two hours dedicated entirely to peptides. He covers BPC-157 mechanisms, GH secretagogues, the tumor risk warning, and his personal sermorelin use. This is where he shared his BPC-157 herniated disc story and gave his clearest breakdown of peptide categories [8].

Episode 2: “Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity” (October 7, 2024) — A practitioner-focused conversation covering real-world protocols. Key topics: tesamorelin for visceral fat, Pentadeca Arginate as a BPC-157 alternative, combining GH secretagogues, and the FDA compounding restrictions. This is where he confirmed switching away from BPC-157 due to availability [9].

Guest appearances: Huberman has also discussed peptides on other podcasts, including conversations with Dr. Peter Attia and on various health-focused interview shows. His messaging stays consistent — cautious optimism about therapeutic peptides combined with frank acknowledgment of limited human data.

Huberman on GH Secretagogues vs. Direct HGH

One of Huberman’s clearest positions: he strongly favors growth hormone secretagogues over direct exogenous HGH injection.

The distinction matters. Exogenous HGH (like Humatrope or Genotropin) delivers a flat dose of synthetic growth hormone directly into the bloodstream. This bypasses the pituitary gland entirely and produces a non-physiological, sustained elevation in GH levels. Over time, this can suppress the pituitary’s natural GH production through negative feedback [8].

Secretagogues — sermorelin, tesamorelin, CJC-1295/ipamorelin — work differently. They signal the pituitary to release its own GH in natural pulses. The body’s feedback mechanisms stay intact. You get elevated GH, but in a pattern that mimics what a younger, healthy pituitary would produce on its own.

Huberman has framed this as “working with your biology rather than overriding it.” His specific concerns with direct HGH include:

Pituitary suppression — long-term exogenous GH can reduce natural production
Flat GH levels vs. pulsatile release — the body responds differently to sustained vs. pulsed GH exposure
Higher cost — pharmaceutical HGH runs $500–$2,000+ per month vs. $150–$400 for secretagogues
Stronger tumor growth concern — direct HGH delivers higher peak levels, amplifying the angiogenesis risk

He’s also noted that for most people seeking general health, sleep improvement, and recovery benefits, secretagogues deliver enough of a boost without the risks of supraphysiological GH doses. Exogenous HGH is more appropriate for diagnosed growth hormone deficiency under endocrinologist supervision.

For a deeper comparison, see our guide on sermorelin vs. HGH.

Deeper Look at His Sermorelin Protocol

Beyond the basics (3–5 nights per week, subcutaneous, before bed), Huberman has shared additional details across episodes:

Timing: He injects 30–60 minutes before sleep, on an empty stomach. This matters because food — particularly carbohydrates and fats — blunts growth hormone release. The fasted state allows the sermorelin-triggered GH pulse to reach its full amplitude during early deep sleep stages [2].

Cycling: Huberman doesn’t appear to use sermorelin continuously year-round. He’s referenced taking breaks, consistent with the cycling approach many peptide protocols recommend. Common cycling patterns for sermorelin include 5 days on / 2 days off (weekdays only), or 3 months on / 1 month off. The reasoning: periodic breaks may prevent pituitary desensitization to GHRH stimulation.

What he stacks it with: Huberman’s broader protocol isn’t just sermorelin in isolation. He’s discussed using it alongside his well-known sleep optimization stack (magnesium threonate, theanine, apigenin) and his general health supplements. He hasn’t publicly confirmed stacking sermorelin with other peptides simultaneously, though the Koniver episode discussed combining sermorelin or tesamorelin with ipamorelin for enhanced GH release.

For standard dosing ranges, our sermorelin dosage guide covers what clinicians typically prescribe.

Huberman fields frequent audience questions about peptides he hasn’t endorsed. A few stand out:

MK-677 (Ibutamoren): While he’s categorized MK-677 as a GH secretagogue, Huberman has expressed reservations about its side effect profile. MK-677 is an oral compound (not technically a peptide) that raises GH levels for an extended period — up to 24 hours per dose. This prolonged elevation increases insulin resistance, appetite, and water retention more than injectable secretagogues with shorter half-lives. He’s mentioned it as an option but hasn’t endorsed personal use.

PT-141 (Bremelanotide): Huberman has discussed melanocortin receptor agonists in the context of sexual health but hasn’t recommended PT-141 for general use. He’s noted its FDA approval (as Vyleesi for hypoactive sexual desire in women) while pointing out side effects like nausea and blood pressure changes that limit its appeal for off-label use.

Follistatin and Myostatin Inhibitors: These muscle-growth-focused compounds come up frequently in audience questions. Huberman has been skeptical, noting that myostatin inhibition sounds promising on paper but the clinical reality has been disappointing. The muscle gains seen in animal knockouts haven’t translated well to human peptide interventions, and the long-term safety data is essentially nonexistent.

AOD-9604: This growth hormone fragment marketed for fat loss has limited clinical support. Huberman hasn’t discussed it at length, which itself signals something — he tends to focus on peptides with either solid data or compelling mechanisms, and AOD-9604 has struggled to demonstrate consistent efficacy in human trials.

His Warnings and Caveats

This is where Huberman separates himself from peptide cheerleaders. He’s consistently vocal about risks:

Tumor Growth Risk

His strongest warning: any peptide that promotes angiogenesis (new blood vessel formation) can potentially feed tumor growth. This applies to BPC-157, TB-500, and GH secretagogues.

“If you have a tumor someplace and it’s small, taking exogenous growth hormone or increasing the amount of growth hormone that you release by taking one of these peptides will increase the size of that tumor,” Huberman stated.

His recommendation: if you have any cancer history, suspicious lumps, or tumor risk factors, avoid these peptides entirely.

The Animal Data Problem

Huberman repeatedly stresses that BPC-157 data is almost entirely from rodent studies. No large-scale human clinical trials exist. The thousands of positive anecdotal reports are encouraging but don’t substitute for controlled trials.

Quality and Sourcing Concerns

He’s discussed the challenge of obtaining pharmaceutical-grade peptides, especially from grey market sources vs. prescription. His consistent recommendation: work with a physician who prescribes from a licensed compounding pharmacy.

For more on peptide safety broadly, see our guide on whether peptides are safe.

The FDA Reclassification Factor

Huberman’s October 2024 conversation with Dr. Koniver directly addressed the FDA’s actions against certain compounded peptides. BPC-157 was placed on the FDA’s “difficult to compound” list, restricting its availability through 503A pharmacies.

This led to practitioners pivoting to alternatives like Pentadeca Arginate and emphasizing FDA-approved options like sermorelin and tesamorelin.

Huberman’s perspective is nuanced. He acknowledges that the regulatory changes frustrate patients who genuinely benefited from compounds like BPC-157. At the same time, he’s pointed out that the unregulated peptide market had real quality control problems — degraded products, mislabeled concentrations, and bacterial contamination from non-sterile manufacturing.

His position lands somewhere in the middle: the FDA’s approach may be overly broad, but the underlying concern about unregulated compounds being widely sold without clinical oversight is legitimate. He’s advocated for a pathway that preserves physician access to compounds with strong anecdotal support while pushing for the human clinical trials that would settle the evidence question.

For the full regulatory picture, see our guide on FDA peptide reclassification in 2026. The Joe Rogan peptides story follows a similar arc — widespread enthusiasm meeting regulatory reality.

How to Get Peptides Prescribed

Based on Huberman’s approach and recommendations:

Find a physician experienced with peptides. Not every doctor understands peptide therapy. Look for providers specializing in functional medicine, anti-aging, or sports medicine. Our peptide doctor near me guide can help.
Get comprehensive blood work first. Huberman’s own approach involves monitoring biomarkers. At minimum, you want a complete hormonal panel, metabolic markers, and cancer screening appropriate for your age.
Use a licensed compounding pharmacy. Avoid grey market research peptides. Prescription peptides from 503A or 503B compounding pharmacies provide pharmaceutical-grade quality.
Consider telehealth options. If local providers are limited, online peptide therapy platforms connect you with experienced prescribers. Some options are covered in our Hone Health review.
Start with FDA-approved compounds. Sermorelin is a reasonable starting point given its approved status and Huberman’s personal experience with it.

FAQ

What peptides does Andrew Huberman take?▼

Huberman has publicly discussed using two peptides personally: sermorelin (3–5 nights per week before bed for sleep and recovery) and BPC-157 (for treating a herniated disc). He’s discussed many others — including TB-500, ipamorelin, CJC-1295, and tesamorelin — on his podcast without confirming personal use.

Does Huberman recommend BPC-157?▼

He’s shared his positive personal experience but is careful not to broadly “recommend” it. He consistently points out that BPC-157 research is limited to animal studies, warns about tumor growth risks from its angiogenesis-promoting effects, and emphasizes the need for medical supervision.

What is Huberman’s sermorelin protocol?▼

Huberman takes sermorelin subcutaneously 3–5 nights per week before bed. He reports deeper sleep with vivid dreams, better exercise recovery, but no significant body composition changes. He hasn’t publicly disclosed his exact dosage. Our sermorelin dosage guide covers standard protocols.

Has Huberman discussed the FDA peptide ban?▼

Yes. In his October 2024 episode with Dr. Craig Koniver, he directly addressed BPC-157’s restricted compounding status and discussed Pentadeca Arginate as an alternative. He’s noted the tension between patient access and regulatory oversight.

Where does Huberman get his peptides?▼

Huberman hasn’t named specific pharmacies, but he consistently recommends working with a licensed physician who prescribes through a compounding pharmacy. He explicitly warns against using grey market research peptide vendors.

Sources

Walker, R.F. “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?” Clinical Interventions in Aging, 2006. PMID: 18044068
Vittone, J., et al. “Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.” Metabolism, 1997. DOI: 10.1016/S0026-0495(97)90174-8
Sikiric, P., et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current Neuropharmacology, 2016. DOI: 10.2174/1570159X13666160502153022
Seiwerth, S., et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lesson from Tendon, Ligament, Muscle and Bone Healing.” Current Pharmaceutical Design, 2018. DOI: 10.2174/1381612824666180712110447
Goldstein, A.L., et al. “Thymosin beta4: a multi-functional regenerative peptide.” Expert Opinion on Biological Therapy, 2012. DOI: 10.1517/14712598.2012.634793
Raun, K., et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998. DOI: 10.1530/eje.0.1390552
Falutz, J., et al. “Effects of tesamorelin on body composition and metabolic health in HIV.” New England Journal of Medicine, 2007. DOI: 10.1056/NEJMoa074658
Huberman, A.D. “Benefits & Risks of Peptide Therapeutics for Physical & Mental Health.” Huberman Lab Podcast, April 1, 2024. https://www.hubermanlab.com/episode/benefits-risks-of-peptide-therapeutics-for-physical-mental-health
Huberman, A.D. & Koniver, C. “Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity.” Huberman Lab Podcast, October 7, 2024. https://www.hubermanlab.com/episode/dr-craig-koniver-peptide-hormone-therapies-for-health-performance-longevity